ALX Oncology Holdings (ALXO) Stock Overview
A clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
ALXO Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
ALX Oncology Holdings Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.75 |
| 52 Week High | US$2.66 |
| 52 Week Low | US$0.40 |
| Beta | 0.50 |
| 1 Month Change | -11.62% |
| 3 Month Change | 17.45% |
| 1 Year Change | 249.09% |
| 3 Year Change | -63.92% |
| 5 Year Change | -96.90% |
| Change since IPO | -94.17% |
Recent News & Updates
Recent updates
ALX Oncology: Evorpacept For ASPEN-09 Presses On With 2 Key Milestones
Mar 01ALX Oncology's Evorpacept Gains Momentum With FDA Fast Track Designations
Sep 12ALX Oncology: Finally Reaching A Reasonable Buy-In Valuation
Jun 27ALX Oncology: Trying To Justify The Hype
Apr 18Is ALX Oncology Holdings (NASDAQ:ALXO) Using Debt In A Risky Way?
Mar 12
ALX Oncology GAAP EPS of -$0.81 misses by $0.18
Aug 08ALX Oncology stock rises on FDA fast track status for evorpacept to treat head/neck cancer
Aug 01ALX Oncology stock rises 14% on evorpacept's FDA orphan drug status for blood cancer
Jun 29Shareholder Returns
| ALXO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -10.7% | 1.7% | 4.2% |
| 1Y | 249.1% | 37.1% | 29.0% |
Return vs Industry: ALXO exceeded the US Biotechs industry which returned 37.8% over the past year.
Return vs Market: ALXO exceeded the US Market which returned 27.4% over the past year.
Price Volatility
| ALXO volatility | |
|---|---|
| ALXO Average Weekly Movement | 13.9% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: ALXO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ALXO's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 43 | Jason Lettmann | www.alxoncology.com |
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma.
ALX Oncology Holdings Inc. Fundamentals Summary
| ALXO fundamental statistics | |
|---|---|
| Market cap | US$223.73m |
| Earnings (TTM) | -US$101.69m |
| Revenue (TTM) | n/a |
Is ALXO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALXO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$101.70m |
| Earnings | -US$101.69m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.77 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 37.5% |
How did ALXO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/13 03:47 |
| End of Day Share Price | 2026/04/13 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ALX Oncology Holdings Inc. is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alethia Young | Cantor Fitzgerald & Co. |
| Li Wang Watsek | Cantor Fitzgerald & Co. |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |